PMID: 9416386Jan 7, 1998Paper

Extrapyramidal reactions and the selective serotonin-reuptake inhibitors

The Annals of Pharmacotherapy
C F Caley

Abstract

To review the known published reports of extrapyramidal reactions (EPRs) associated with the use of selective serotonin-reuptake inhibitors (SSRIs). Information was selected from a MEDLINE search (January 1990 to January 1996) of English-language medical literature. Manual searches of pertinent journal article bibliographies were also performed. Appropriate information from all reports obtained was included, with specific attention directed toward patient age, gender, primary psychiatric diagnosis, total daily SSRI dosage, dosage escalation strategy, and concurrent psychotropic medications. Reports of EPRs associated with SSRI use have been accumulating in the medical literature for several years. More commonly associated with high-potency antipsychotics, EPRs can have an adverse impact on medication compliance and hospital readmissions. The proposed hypothesis for EPRs occurring with SSRI use involves serotonin's inhibitory actions on extrapyramidal dopamine activity. Other possible contributing factors include pharmacokinetic interactions or drug-disease interactions. EPRs may include dystonias, dyskinesias, akathisia, parkinsonism, exacerbations of Parkinson's disease, and possibly the neuroleptic malignant syndrome. The maj...Continue Reading

References

Apr 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·V Wils
Oct 1, 1991·The American Journal of Psychiatry·C L Budman, R D Bruun
Jun 1, 1991·The American Journal of Psychiatry·H Sternbach
Apr 1, 1991·Journal of Clinical Psychopharmacology·B A Fallon, M R Liebowitz
Sep 15, 1990·Biological Psychiatry·M Halman, D S Goldbloom
Oct 1, 1989·The American Journal of Psychiatry
Mar 1, 1989·The American Journal of Psychiatry·J L Tate
Apr 1, 1985·Biological Psychiatry·B E Suranyi-CadotteS Gauthier
Nov 1, 1988·The Journal of Nervous and Mental Disease·G AddonizioP M Stoll
Feb 1, 1988·Clinical Neuropharmacology·C Bernick
May 1, 1988·The American Journal of Psychiatry·H K Lee
May 1, 1972·Neurology·T N ChaseA M Watanabe
Nov 29, 1969·British Medical Journal·S Brandon
May 1, 1984·The American Journal of Psychiatry·K R KrishnanE H Ellinwood
Dec 1, 1983·Annals of Internal Medicine·M B Jacobs
Mar 1, 1995·Biological Psychiatry·L A Adler, B M Angrist
Dec 1, 1994·Neurology·F J Jiménez-JiménezE García-Albea
Dec 19, 1994·The American Journal of Medicine·C L DeVane
Jun 1, 1994·The Australian and New Zealand Journal of Psychiatry·A ManderN Christophidis
Dec 1, 1993·Journal of Clinical Psychopharmacology·M R LavinS H Block
Jun 1, 1993·Journal of Clinical Psychopharmacology·L D LaPorta
Jun 1, 1993·Journal of Clinical Psychopharmacology·M S George, M R Trimble
May 1, 1993·The American Journal of Psychiatry·R Ketai
Mar 1, 1996·Comprehensive Psychiatry·C F BaldassanoG S Sachs
Jun 1, 1996·Journal of Clinical Psychopharmacology·S D Botsaris, J M Sypek
Sep 1, 1996·Psychiatric Services : a Journal of the American Psychiatric Association·S L Dubovsky, M Thomas

❮ Previous
Next ❯

Citations

Nov 19, 2003·Journal of Clinical Psychopharmacology·Vassilis P KontaxakisGeorge N Christodoulou
Dec 13, 2005·Clinical Neuropharmacology·Matthew M Parvin, Conrad M Swartz
Jul 7, 2009·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Leonardo Caixeta
Jan 15, 2009·Journal of Clinical Psychopharmacology·John D MatthewsMaurizio Fava
Jul 29, 2009·Harvard Review of Psychiatry·Zeina ChemaliGregory Fricchione
Jun 13, 2003·The Neurologist·J A Van Gerpen
Jun 14, 2006·Biopharmaceutics & Drug Disposition·Laurian VlaseMircea Nanulescu
Dec 13, 2007·Palliative Medicine·Ian Back, Mark Taubert
Jun 14, 2008·Journal of Neurophysiology·Moshe Rav-AchaYosef Yarom
Nov 8, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Agnieszka Dyduch, Maria Załuska
Nov 22, 2013·The Annals of Pharmacotherapy·Brian D Host, Walker Sloan
Apr 25, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·Е B Lyubov, S A Ignatenko
Jun 21, 2001·The Annals of Pharmacotherapy·G GarciaB L Dansky
Oct 7, 2008·Clinical Neuropharmacology·Toshifumi MuraokaShigeto Yamada
Nov 6, 2007·The International Journal of Neuropsychopharmacology·Aysegul Yolga Tahiroglu, Ayse Avci
Apr 7, 2007·Clinical Neuropharmacology·Pedro J Garcia RuizPablo Carnal
Jul 2, 2015·Journal of Child and Adolescent Psychopharmacology·Nathaniel SharonKara Martinez
Jan 23, 2016·Journal of Clinical Pharmacy and Therapeutics·M GentiliS Radice
Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S TeseiG Pezzoli
Apr 14, 1999·The Annals of Pharmacotherapy·V PalopI Martínez-Mir
Sep 24, 2008·Internal Medicine Journal·S BilenN Oztekin
Sep 1, 2007·Journal of Clinical Neurology·Jeong-Min KimManho Kim
Jul 18, 2015·The Annals of Pharmacotherapy·Jessica M Hawthorne, Charles F Caley
Jan 4, 2007·European Journal of Clinical Pharmacology·Maurits E L ArbouwToine C G Egberts
Mar 17, 2011·Clinical Neuropharmacology·Vladimir Miletić, Maja Relja
Jan 31, 2002·The Annals of Pharmacotherapy·Alexander A Fisher, Michael W Davis
Jan 2, 2007·Journal of Psychosocial Nursing and Mental Health Services·Robert H Howland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here